Trial Profile
A Phase I Study of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells in Combination With JSMD194, a Small Molecule Inhibitor of Gamma Secretase, in Patients With Relapsed or Persistent Multiple Myeloma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 10 Jan 2024
Price :
$35
*
At a glance
- Drugs Crenigacestat (Primary) ; FCARH 143 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Multiple myeloma
- Focus Adverse reactions; First in man
- 04 Jan 2024 Status changed from active, no longer recruiting to discontinued.
- 29 Dec 2023 Status changed from suspended to active, no longer recruiting.
- 12 Dec 2023 Results an analysis of the bone marrow aspirates collected at enrollment and again within 12 hours of the third run in dose, presented at the 65th American Society of Hematology Annual Meeting and Exposition